The chemical giant’s intellectual-property strategy and its operational machine are moving in tandem these days, even if the two rarely intersect. A patent infringement suit filed in Midland, Texas, against Apple over Face ID technology represents the latest example of how deeply BASF’s tentacles reach beyond the traditional chemistry business, while closer to home, the company has quietly switched on a rebuilt production line and pushed through price increases across several polymer feedstocks.
The legal action, brought by Ludwigshafen-based subsidiary trinamiX, alleges that Apple’s Face ID system in the iPhone 15, 16 and 17 models, along with the iPad Pro, infringes seven patents related to skin and material recognition. At the heart of the dispute are anti-spoofing methods that distinguish genuine human skin from replicas — a critical layer of security in biometric facial authentication. trinamiX, itself a BASF spin-off specializing in sensing technology, is seeking damages and an injunction barring further use of the patented processes.
Patent litigation in Texas typically drags on for months, if not years, before a ruling lands or the parties opt for a settlement. The outcome here remains very much an open question. Should the court side with trinamiX, the implications could extend beyond licensing fees to regulatory pressure on how Apple designs its devices. For BASF, however, the case carries more strategic symbolism than near-term financial weight — the potential monetary leverage is modest relative to group revenue.
That distinction matters for shareholders watching the stock. The shares closed Friday at EUR 53.33, down 0.2 percent on the day, but the broader trajectory tells a more constructive story. Over the past 30 days, the stock has gained 5.3 percent, and it sits just 3.1 percent below its 52-week high of EUR 55.05, reached in April. Year-to-date, the advance stands at 20 percent.
What has been driving that momentum is a combination of capital-allocation discipline and operational execution. The share buyback program launched just over a week ago — worth up to EUR 1 billion as part of a broader envelope of at least EUR 4 billion running through 2028 — has lent support, with the stock adding 1.8 percent since the program was announced. That follows the late-June completion of the sale of large parts of the Coatings business to Carlyle, a divestment that has coincided with a 14.1 percent improvement in the share price.
On the operational front, BASF has been busy on multiple tracks. The newly modernized facility at the Ludwigshafen Verbund site, producing acid chlorides and chloroformates, was officially brought onstream in early September, confirmed through two successive corporate announcements. Around the same time, price increases for caprolactam, polyamide 6 and polyamide-6/66 copolymers took effect in North America on September 1, alongside hikes for neopentyl glycol in both Europe and North America. The adjustments, flagged in late August, cover key inputs for the plastics and fibers industries and signal the company’s determination to hold pricing power in a margin-constrained environment.
Should investors sell immediately? Or is it worth buying BASF?
The Agricultural Solutions division is also investing ahead of the curve, pouring money into a new climate center in Limburgerhof slated to begin operations in the first half of 2027. The facility is designed to accelerate approval processes for crop protection products amid tightening regulatory demands. Separately, BASF is collaborating with Shell and China Baowu on a CCUS cluster aimed at industrial-scale CO2 capture, with an eventual target of ten million tons annually.
Recognition has come in other forms as well. The company’s Plantapon Amino ASP received the Ringier Technology Innovation Award 2026 in the Functional Chemicals – Surfactants category, an accolade that rarely moves the needle on valuation but reinforces the narrative of a group that continues to invest in R&D even as it restructures.
One note of caution has emerged from the analyst community, however. Midweek, mwb research trimmed its rating on the stock from “Buy” to “Hold,” though it left its price target unchanged at EUR 55 — a subtle signal that much of the near-term upside may already be reflected in the current price, without any deterioration in the underlying fundamental view.
For investors, the composite picture is of a company pressing forward on several fronts at once: defending intellectual property in a Texas courtroom, modernizing production at home, asserting pricing power abroad, and returning capital to shareholders — all while keeping the shares within striking distance of their yearly peak.
Ad
BASF Stock: Buy or Sell?! New BASF Analysis from September 5 delivers the answer:
The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 5.
BASF: Buy or sell? Read more here...
